Decline in PSA levels is associated with improved survival

Categories: Winter 2022
Sandy blue curled wave. p7jpeg
“In all things of nature there is something of the marvelous.” – Aristotle
©Sanford Radom, MD

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is inceasingly included in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). 

In this analysis, 184 patients were treated with 177Lu-PSMA RLT. Response to treatment was defined as decrease in PSA levels 8 weeks after the first cycle of RLT. Any decline of more than 50% was compared in responders and non-responders. A total of 114/184 patients showed any PSA decline, results found individuals exhibiting a PSA decline of more than 50% had overall survival of 19 months as compared with only 8 months in the non-responders.

In mCRPC patients scheduled for radioligand therapy, early biochemical response was tightly linked to prolonged survival irrespective of the magnitude of PSA decline. RLT therapy should be continued even in patients with PSA decrease of less than 50%.

The Prostate. 2022, July 21;




Subscribe to Quest

"*" indicates required fields


This email address is only for subscribing or unsubscribing to or from Quest. Dr. Catalona cannot respond to questions concerning your Personal Health Information (PHI) that could identify you as an individual. This is a "cyber-security measure" for your protection that will help prevent anyone from legally or illegally accessing your personal health information.

Delivery Method (How do you want to receive your Quest publication?)*